TY - JOUR
T1 - Changes in pediatric health-related quality of life in cystic fibrosis after iv antibiotic treatment for pulmonary exacerbations
AU - Modi, Avani C.
AU - Lim, Crystal S.
AU - Driscoll, Kimberly A.
AU - Piazza-Waggoner, Carrie
AU - Quittner, Alexandra L.
AU - Wooldridge, Jamie
N1 - Funding Information:
Funding/Support This study was supported by a post-doctoral training grant from the National Institutes of Health (T32 DK063929) to the first, third, and fourth author.
Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2010/3
Y1 - 2010/3
N2 - Intravenous (IV) antibiotic therapy for pulmonary exacerbations (PE) has been shown to improve pulmonary functioning for patients with cystic fibrosis (CF); however, little is known about its effects on pediatric health-related quality of life (HRQOL). This prospective study assessed the impact of IV treatment of a PE on generic and CF-specific HRQOL for children and adolescents with CF. Participants included 52 children and adolescents with CF experiencing a PE (M age = 13.6 years; 54% males; M-{{{\text{FEV}}-{1\% } }} predicted = 58.8%). HRQOL, pulmonary functioning, and body mass index were assessed before and after IV antibiotic treatment. Results of this prospective, observational study indicated significant improvements on CFQ-R Respiratory (M change score = 11.7; 95% CI = 6.3-17.1; p < .0001) and Weight (M change score = 15.9; 95% CI = 7.9-23.8; p < .0001) scales. The CF-specific measure was more sensitive to changes in HRQOL than the generic instrument. These data suggest that CF-specific HRQOL improves with treatment for a PE with IV antibiotics. The noted statistically and clinically significant changes in the CFQ-respiratory scale indicate that the measure may be beneficial to pulmonary health care teams.
AB - Intravenous (IV) antibiotic therapy for pulmonary exacerbations (PE) has been shown to improve pulmonary functioning for patients with cystic fibrosis (CF); however, little is known about its effects on pediatric health-related quality of life (HRQOL). This prospective study assessed the impact of IV treatment of a PE on generic and CF-specific HRQOL for children and adolescents with CF. Participants included 52 children and adolescents with CF experiencing a PE (M age = 13.6 years; 54% males; M-{{{\text{FEV}}-{1\% } }} predicted = 58.8%). HRQOL, pulmonary functioning, and body mass index were assessed before and after IV antibiotic treatment. Results of this prospective, observational study indicated significant improvements on CFQ-R Respiratory (M change score = 11.7; 95% CI = 6.3-17.1; p < .0001) and Weight (M change score = 15.9; 95% CI = 7.9-23.8; p < .0001) scales. The CF-specific measure was more sensitive to changes in HRQOL than the generic instrument. These data suggest that CF-specific HRQOL improves with treatment for a PE with IV antibiotics. The noted statistically and clinically significant changes in the CFQ-respiratory scale indicate that the measure may be beneficial to pulmonary health care teams.
KW - Disease-specific
KW - Intravenous antibiotics
KW - Minimal clinically important difference
KW - Patient-reported outcomes
UR - http://www.scopus.com/inward/record.url?scp=77249085575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77249085575&partnerID=8YFLogxK
U2 - 10.1007/s10880-009-9179-2
DO - 10.1007/s10880-009-9179-2
M3 - Article
C2 - 20157799
AN - SCOPUS:77249085575
VL - 17
SP - 49
EP - 55
JO - Journal of Clinical Psychology in Medical Settings
JF - Journal of Clinical Psychology in Medical Settings
SN - 1068-9583
IS - 1
ER -